{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 50,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses an antibody diagram to annotate specific technical advantages of the SPY002 molecule.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/30",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.17,
        "y": 0.28
      },
      "kind": "image",
      "text": "Antibody diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc201ead-0f8c-4f77-90d0-e9c9036e78b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.02,
        "y": 0.6
      },
      "kind": "list",
      "text": "High concentration SC: Ability to formulate at >150 mg/mL with low viscosity; Citrate-free formulation may improve patient comfort",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fff8d1a-4937-4226-86cc-2608fb2ad0b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.53,
        "y": 0.6
      },
      "kind": "list",
      "text": "Significantly extended half-life: Q8-Q12W dosing based on validated half-life extension technology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39db5155-d9b8-4f5b-9a20-dfb93176934b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.53,
        "y": 0.25
      },
      "kind": "list",
      "text": "Novel IP for composition of matter into 2040s",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "578532df-53bb-4409-a6a7-77840665c42e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "list",
      "text": "PRA023 clinically validates pharmacology and therapeutic effect of MOA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b42bb906-3ef3-44fc-93e4-32df2eab155a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.39
      },
      "kind": "table",
      "text": "SPY002 target profile: Efficacy >= PRA023, Subcutaneous 300 mg dose, Q8W or Q12W dose",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5d3ea81-318b-43e1-bce1-f25377af75d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY002 exploits biology that has been validated by PRA023 and is designed to be best-in-class",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39c24b82-34d1-40ff-8d0c-ce526378b638",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "ad43fdc3-d312-4145-8354-8473891ffe74",
      "evidence": "The slide uses a list/bullet to present key points about SPY002's design and target profile.",
      "confidence": 0.8
    },
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "3f8648bc-29c5-4a79-a67d-c2f2633c50b7",
      "evidence": "The table/data component could be related to a waterfall chart or a value bridge, but it's not clear.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}